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Abstract 
Purpose A case of leukopenia in a patient receiving colchicine for calcium pyrophosphate dihydrate 
deposition disease, or pseudogout, is reported.  
Summary An 85-year-old man experienced leukopenia likely due to colchicine. His medical history 
included chronic lymphocytic leukemia (CLL), pseudogout, osteoarthritis, and hypertension. In February 
2011, his white blood cell (WBC) count was 2700 cells/μL, and his absolute neutrophil count (ANC) was 
2200 cells/μL. Colchicine 0.6 mg orally daily was initiated in March for the prophylaxis of pseudogout. 
His WBC count decreased, and his colchicine dosage was reduced to 0.6 mg every other day. Despite this 
decreased dosage, his WBC count and ANC were 600 and 100 cells/μL, respectively, in September. In 
October, the patient received chemotherapy for presumed worsening of his CLL. One month later, his 
WBC count and ANC were 400 and 200 cells/μL, respectively. Subcutaneous filgrastim was 
administered, and colchicine was discontinued. At the end of November, he received another cycle of 
chemotherapy followed by pegfilgrastim. On the day of pegfilgrastim administration, the patient's WBC 
count and ANC were 2000 and 1300 cells/μL, respectively. Two weeks later, his WBC count was 8800 
cells/μL, and his ANC was 8300 cells/μL. Daily colchicine was restarted at the end of December. Two 
months later, his WBC count and ANC were 800 and 500 cells/μL, respectively. Given the symptomatic 
relief with colchicine, therapy was continued with close monitoring.  














Colchicine is widely used for both the treatment and prophylaxis of gout. Gastrointestinal effects 
typically precede severe colchicine toxicity; therefore, treatment is usually discontinued before 
significant toxicity develops.1 Colchicine inhibits leukocyte chemotaxis and phagocytosis, urate 
crystal disposition, and microtubule assembly via inhibition of β-tubulin polymerization in cells 
(including leukocytes). These actions prevent the neutrophil activation, degranulation, and 
migration associated with mediating gout symptoms without producing any inherent analgesic or 
antihyperuricemic effects. A rare adverse effect related to colchicine is leukopenia, which may be 
caused by the drug's inhibition of leukocyte migration into tissues and its antimitotic effects.2 The 
occurrence of leukopenia secondary to colchicine use at low-to-normal dosages has not adequately 
been characterized in the literature. We describe a case of leukopenia in a patient receiving 
colchicine for calcium pyrophosphate dihydrate deposition disease, or pseudogout. 
Case report 
An 85-year-old Caucasian man (84 kg, 68 in) with a normal serum creatinine concentration (1 
mg/dL at baseline) developed leukopenia after receiving treatment with colchicine for pseudogout. 
His medical history included chronic lymphocytic leukemia (CLL), pseudogout, osteoarthritis, and 
hypertension. His medications included acetaminophen 500–1000 mg orally every four to six 
hours as needed for pain, doxazosin 2 mg orally daily at bedtime, polysaccharide–iron complex 
150 mg (of iron) orally daily, omeprazole 20 mg orally daily, and testosterone enanthate 200 mg 
intramuscularly once monthly. 
In February 2011, his white blood cell (WBC) count was 2700 cells/μL, and his absolute neutrophil 
count (ANC) was 2200 cells/μL. Colchicine 0.6 mg orally daily was initiated in March for the 
prophylaxis of pseudogout. In June 2011, his WBC count was 1200 cells/μL, and his ANC was 
800 cells/μL. His WBC count continued to decrease to 800 cells/μL in July, with an ANC of 400 
cells/μL. In August, the patient's colchicine dosage was reduced to 0.6 mg every other day. Despite 
this decreased dosage, his WBC count and ANC were 600 and 100 cells/μL, respectively, in 
September. 
In October 2011, the patient received chemotherapy for presumed worsening of his CLL. The 
regimen consisted of rituximab i.v. on day 1 and bendamustine i.v. on days 1 and 2. Pegfilgrastim 
was administered subcutaneously on day 3. One month later, his WBC count and ANC were 400 
and 200 cells/μL, respectively. Subcutaneous filgrastim was administered, and the colchicine was 
discontinued. 
 
Two weeks later, the patient's WBC count and ANC increased to 1800 and 1400 cells/μL, 
respectively. These counts were maintained for two weeks, with a WBC count of 1900 cells/μL at 
the end of November; his ANC remained the same. At the end of November, he received another 
cycle of chemotherapy followed by pegfilgrastim. On the day of the pegfilgrastim administration, 
the patient's WBC count and ANC were 2000 and 1300 cells/μL, respectively. Two weeks later, 
his WBC count was 8800 cells/μL, and his ANC was 8300 cells/μL. 
 
Daily colchicine was restarted at the end of December. Two months later, his WBC count was 
decreased to 800 cells/μL, and his ANC was 500 cells/μL. Colchicine controlled the painful joints 
related to the patient's pseudogout. Cessation of colchicine treatment was consistently followed by 
a flare-up of pseudogout symptoms. Given the symptomatic relief with colchicine, therapy was 
continued with close monitoring. 
 
Due to the association between the patient's WBC and ANC values with initiation and repeated 
challenge of colchicine, the patient was believed to have developed leukopenia secondary to 
colchicine. 
Discussion 
To our knowledge, colchicine-associated leukopenia in a patient being treated for pseudogout has 
not previously been reported. With a score of 6 on the Naranjo et al.3 scale, this event was deemed 
a probable adverse reaction associated with colchicine.  
A confounding variable is the intermittent treatment of CLL with rituximab and bendamustine. 
Although this treatment may be considered a possible cause of the patient's leukopenia, the initial 
occurrence and recurrence of leukopenia was closely associated with the timing of the colchicine 
therapy and occurred before the patient received his first cycle of chemotherapy and again when 
chemotherapy was not being administered. Further, the patient was treated with a colony-
stimulating factor (CSF) to stimulate neutrophil growth during the first cycle of chemotherapy. 
Despite CSF therapy, resolution of neutropenia did not occur until colchicine was discontinued. 
During cycle 2, when colchicine was not given, CSF administration resulted in full resolution of 
any hematologic toxicity associated with the chemotherapy. Lastly, hepatic impairment leading to 
impaired colchicine metabolism was not likely, as (1) the patient's aspartate transaminase and 
alanine transaminase concentrations remained normal during this time frame, (2) acetaminophen 
was used only occasionally, and (3) the patient reported no alcohol consumption.  
Reports describing leukopenia in adult patients receiving varying dosages and durations of 
colchicine have been published.1,4,5 In one report, a 68-year-old man experiencing an acute gout 
attack received colchicine therapy, and his WBC count decreased from 16,700 to 2,000 cells/μL 
over the course of nine days.1 The colchicine dosage was reduced, and the drug was subsequently 
discontinued, followed by treatment with filgrastim. The patient's cell counts recovered after 
colchicine discontinuation. Ben-Chetrit and Navon4 described the case of a 19-year-old woman 
receiving colchicine for familial Mediterranean fever. The patient developed leukopenia, and 
colchicine was discontinued, after which time her cell counts recovered. Lastly, Lee and 
colleagues5 described the cases of two adults with Behçet's disease whose WBC counts dropped 
during treatment with colchicine. In both cases, colchicine was discontinued, patients were treated 
with granulocyte CSFs, and their cell counts recovered thereafter. Our patient received lower 
colchicine dosages than in these previously reported cases yet continued to experience hematologic 
effects, indicating that this effect may not have been dosage related. 
Colchicine was a likely cause of leukopenia in our patient. Monitoring of WBCs and neutrophils 
may be warranted in patients receiving long-term colchicine therapy, even at low-to-normal 
dosages. 
Conclusion 
A patient with CLL developed leukopenia in association with colchicine administration for pseudogout. 
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